CGC / Canopy Growth sees bigger 4Q loss as company cuts BioSteel staff

Canopy Growth's hopes hinge on federal marijuana legalization in the U.S. Federal legalization could still be years away, and there's no guarantee tha more_horizontal

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business. more_horizontal

Investors and traders in the Canadian cannabis market are closely monitoring the leading Canadian cannabis stocks as November draws near. Recent years more_horizontal

The current activity in the U.S. House of Representatives doesn't benefit cannabis companies. While the chamber lacks a Speaker, it can't conduct any more_horizontal

As we enter the fourth quarter of 2023 the cannabis sector is progressing into the future. More companies are working on various ventures and developi more_horizontal

Cannabis stocks have been stagnant or declining due to cash burn and regulatory challenges. Despite this, many bulls have once again begun expecting a more_horizontal

Canopy Growth's cash burn is high but could improve as the company stops funding BioSteel. Dilution, however, may become a much bigger problem for inv more_horizontal

Pity the average cannabis stock investor. Since 2021, shares of the largest cannabis fund, the AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS ) ha more_horizontal